GOCOVRIHCP.COM: Keyword Density Checker

Total words: 4077 | 2-word phrases: 1058 | 3-word phrases: 1196 | 4-word phrases: 1259

PAGE INFO

Title	Try to keep the title under 60 characters (77 characters) GOCOVRI® (amantadine) Extended Release Capsules - Parkinson's Treatment
Description	Try to keep the meta description between 50 - 160 characters (167 characters) GOCOVRI® (amantadine) an extended-release treatment for both dyskinesia and OFF time in patients with Parkinson’s disease. See safety & prescribing information.
Keywords	Meta keywords are not recommended anymore (0 characters)
H1	H1 tag on the page (25 characters) GO with more GOOD ON time

#	Keyword	Frequency	Density
1	in patients with	9	0.75%
2	with parkinson’s disease	7	0.59%
3	good on time	7	0.59%
4	and orthostatic hypotension	6	0.50%
5	with placebo baseline	6	0.50%
6	dyskinesia and off	5	0.42%
7	activities of daily	4	0.33%
8	video cover click	4	0.33%
9	of daily living	4	0.33%
10	during activities of	4	0.33%
11	asleep during activities	4	0.33%
12	falling asleep during	4	0.33%
13	discontinuation of gocovri	4	0.33%
14	and off time	4	0.33%
15	dose reduction or	4	0.33%
16	patients with a	4	0.33%
17	important safety information	4	0.33%
18	dizziness and orthostatic	4	0.33%
19	patients with parkinson’s	4	0.33%
20	information important safety	4	0.33%
21	watch interview with	3	0.25%
22	gocovri treatment paradigm	3	0.25%
23	treatment paradigm efficacy	3	0.25%
24	paradigm efficacy safety	3	0.25%
25	more good on	3	0.25%
26	to watch interview	3	0.25%
27	treatment of dyskinesia	3	0.25%
28	click to watch	3	0.25%
29	extended release capsules	3	0.25%
30	endpoint study 1	3	0.25%

#	Keyword	Frequency	Density
1	asleep during activities of	4	0.32%
2	falling asleep during activities	4	0.32%
3	patients with parkinson’s disease	4	0.32%
4	during activities of daily	4	0.32%
5	in patients with parkinson’s	4	0.32%
6	activities of daily living	4	0.32%
7	dizziness and orthostatic hypotension	4	0.32%
8	dyskinesia and off time	4	0.32%
9	information important safety information	4	0.32%
10	treatment paradigm efficacy safety	3	0.24%
11	gocovri treatment paradigm efficacy	3	0.24%
12	video cover click to	3	0.24%
13	more good on time	3	0.24%
14	cover click to watch	3	0.24%
15	hours with placebo baseline	3	0.24%
16	to watch interview with	3	0.24%
17	for the treatment of	3	0.24%
18	the treatment of dyskinesia	3	0.24%
19	conversations eating gocovri should	2	0.16%
20	vehicle conversations eating gocovri	2	0.16%
21	motor vehicle conversations eating	2	0.16%
22	a motor vehicle conversations	2	0.16%
23	driving a motor vehicle	2	0.16%
24	release capsules is indicated	2	0.16%
25	eating gocovri should ordinarily	2	0.16%
26	require full attention eg	2	0.16%
27	capsules is indicated for	2	0.16%
28	is indicated for the	2	0.16%
29	indicated for the treatment	2	0.16%
30	be discontinued or the	2	0.16%
31	that require full attention	2	0.16%
32	activities that require full	2	0.16%
33	during activities that require	2	0.16%
34	sleepiness during activities that	2	0.16%
35	daytime sleepiness during activities	2	0.16%
36	if a patient develops	2	0.16%
37	extended release capsules is	2	0.16%
38	should be advised to	2	0.16%
39	discontinued or the patient	2	0.16%
40	depression including suicidal ideation	2	0.16%

#	URL	Whois	Check
1	https://www.gocovri.com/	Whois	gocovri.com
2	https://www.facebook.com/GOCOVRI	Whois	facebook.com
3	https://www.gocovri.com/	Whois	gocovri.com
4	https://www.facebook.com/GOCOVRI	Whois	facebook.com
5	https://www.supernus.com/privacy-policy	Whois	supernus.com
6	https://www.supernus.com/cookies-policy	Whois	supernus.com
7	https://www.supernus.com/privacy-policy	Whois	supernus.com
8	https://www.supernus.com/cookies-policy	Whois	supernus.com
9	https://www.supernus.com/terms-of-use	Whois	supernus.com
10	https://www.supernus.com/contact-us	Whois	supernus.com